Stueland Katherine 4
4 · GeneDx Holdings Corp. · Filed Mar 9, 2026
Research Summary
AI-generated summary of this filing
GeneDx CEO Katherine Stueland Receives 3,404 Shares
What Happened
- Katherine Stueland, CEO of GeneDx Holdings Corp. (WGS), acquired 3,404 shares of the company's Class A common stock on March 6, 2026.
- Purchase price was $88.11 per share, for a total cost of $299,926. The Form 4 classifies the transaction as an acquisition/award (code A), not a sale.
Key Details
- Transaction date and price: March 6, 2026 — 3,404 shares at $88.11/share.
- Total value: $299,926 (3,404 × $88.11).
- Shares owned after the transaction: not specified in the filing.
- Filing date: Form 4 filed March 9, 2026 (reported within the standard Form 4 reporting window).
- Footnote: The shares were acquired directly from the issuer under a Subscription Agreement dated March 6, 2026 and the transaction was exempt under Rule 16b-3(d); the purchase price equals the closing price on March 6, 2026.
Context
- This was a direct purchase from the company (not an open-market buy or an option exercise). Purchases by insiders can be more informative to investors than routine sales, but the filing provides only transaction mechanics (no stated motivation).
Insider Transaction Report
Form 4
Stueland Katherine
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Award
Class A Common Stock
[F1]2026-03-06$88.11/sh+3,404$299,926→ 42,087 total
Footnotes (1)
- [F1]Pursuant to a Subscription Agreement executed on March 6, 2026 between GeneDx Holdings Corp. (the "Issuer") and the reporting person, the reporting person acquired 3,404 shares of the Issuer's Class A common stock directly from the Issuer in an exempt transaction pursuant to Rule 16b-3(d) at a purchase price of $88.11 per share, the closing price of the Issuer's Class A common stock on March 6, 2026.
Signature
/s/ Bridget Brown, Attorney-in-Fact|2026-03-09